InventisBio, Co., Ltd. Class A

As of June 30, 2026, InventisBio, Co., Ltd. Class A carries a market capitalization of 10.43B, placing it among publicly traded companies globally. Its enterprise value stands at 9.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

InventisBio, Co., Ltd. Class A's next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, InventisBio, Co., Ltd. Class A has 579.59M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, InventisBio, Co., Ltd. Class A maintains a current ratio of 15.29, meaning it holds 15.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, InventisBio, Co., Ltd. Class A recorded an income tax benefit of -100,214.70 rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 23, 2026, InventisBio, Co., Ltd. Class A's stock has declined approximately 42.38% over the past 52 weeks. The 50-day moving average sits at 18.73, while the 200-day moving average is 21.36.

As of June 30, 2026, InventisBio, Co., Ltd. Class A holds 1.33B in cash and equivalents against 18.80M in total debt, resulting in a net debt position of -1.17B. Total book value stands at 1.41B, with working capital of 1.37B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.